SYNAGEVA BIOPHARMA CORP (GEVA) [Rocket]

In millions, except per share items	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11	Dec-31-10	Dec-31-09	Dec-31-08	Dec-31-07
	10-K	10-K	10-K	10-K/A	10-K	10-K/A	10-K	10-K
Revenue:
Royalty revenue	6.0	7.0	7.0	1.1			11.4	15.7
Collaboration and license revenue	0.5	6.3	7.9	0.6	0.3
Total revenue	6.5	13.4	15.0	2.1	0.6	161.8	11.4	15.7
Total revenue growth	-51.5%	-10.6%	612.4%	252.8%	-99.6%	1325.3%	-27.8%	33.1%
Costs and expenses:
Research and development	142.6	79.6	37.3	17.3	9.9		4.2	11.4
Selling, general and administrative	54.5	27.6	17.4	9.3	3.9		7.7	11.1
Amortization of developed technology	1.5	2.1	3.2	0.5
Total costs and expenses	399.4	220.2	117.0	54.9	27.9		11.9	22.5
Loss from operations	-192.1	-95.9	-43.0	-25.0	-13.1		7.3	25.4
Operating margin	-2959.5%	-717.1%	-287.7%	-1191.9%	-2205.5%		64.5%	161.7%
Other expense, net	-0.2	0.2		-0.3	2.3
Interest income, net	0.3	0.3	0.1	0.0	0.0		2.1	3.0
Loss before provision for income taxes	-192.1	-95.4	-42.9	-25.3
Provision for income taxes	0.5	0.0					-0.3	0.4
Net loss	-192.6	-95.5	-42.9	-25.3	-10.8		8.0	27.4

Basic and diluted net loss per common share	($5.89)	($3.40)	($1.90)	($8.58)	($338.25)		$0.36	$1.24

Weighted average shares used in basic and diluted per common share computations	32.7	28.1	22.6	3.0	0.0